Question 1

What is dalcinonacog alfa and how does it differ from plasma-derived factor IX?

Accepted Answer

Dalcinonacog alfa (Ixinity) is a recombinant coagulation factor IX produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. Unlike plasma-derived factor IX concentrates, which are purified from pooled human plasma donations, dalcinonacog alfa is manufactured in a controlled cell culture system, eliminating the theoretical risk of transmitting blood-borne pathogens such as hepatitis viruses or prions. The recombinant product also offers greater batch-to-batch consistency and does not depend on the availability of donated human plasma. Both forms are functionally equivalent in restoring the coagulation cascade, but recombinant products are generally preferred for newly diagnosed patients due to their superior safety profile.

Question 2

How is dalcinonacog alfa dosed for hemophilia B patients?

Accepted Answer

Dosing of dalcinonacog alfa is individualized based on the severity of the factor IX deficiency, the location and extent of bleeding, the patient's clinical condition, and the desired factor IX activity level. The general formula is: Required IU = body weight (kg) × desired factor IX increase (% or IU/dL) × reciprocal of observed recovery (approximately 1.0 IU/kg per IU/dL). For minor bleeding episodes, target factor IX levels of 20–30% are typically sufficient, while major bleeds or surgical procedures may require levels of 60–100%. For routine prophylaxis, doses of 40–60 IU/kg administered twice weekly have been shown to significantly reduce annualized bleeding rates.

Question 3

What are the most common side effects of dalcinonacog alfa?

Accepted Answer

In clinical trials, the most commonly reported adverse reactions with dalcinonacog alfa included headache, dizziness, nausea, infusion-site reactions (pain, erythema, swelling), and dysgeusia (altered taste). These were generally mild and transient. The most clinically significant potential adverse event is the development of neutralizing antibodies (inhibitors) against factor IX, which can render replacement therapy ineffective. However, no inhibitor development was observed in the pivotal clinical trials of dalcinonacog alfa in previously treated patients. Rare but serious risks include hypersensitivity reactions and thromboembolic events, particularly when factor IX levels are sustained at supraphysiological levels.

Question 4

Can dalcinonacog alfa be used for surgical prophylaxis?

Accepted Answer

Yes, dalcinonacog alfa is indicated for perioperative management (surgical prophylaxis) in hemophilia B patients. For major surgical procedures, pre-operative factor IX activity levels are typically targeted at 80–100% of normal, with maintenance levels of 30–60% sustained for 7–14 days post-operatively depending on the nature of the surgery and the patient's healing progress. Clinical data have demonstrated excellent or good hemostatic efficacy in surgical settings, with successful outcomes in both major and minor procedures without excessive bleeding or the need for alternative hemostatic agents.

Question 5

How does factor IX function in the normal coagulation cascade?

Accepted Answer

Factor IX is a vitamin K-dependent serine protease zymogen that plays a central role in the intrinsic (contact activation) pathway of blood coagulation. When activated to factor IXa — either by factor XIa in the intrinsic pathway or by the tissue factor–factor VIIa complex — it forms the tenase complex with its cofactor factor VIIIa on activated platelet phospholipid surfaces. This complex is the primary physiological activator of factor X, amplifying the coagulation signal by several orders of magnitude compared to factor X activation by factor VIIa–tissue factor alone. Deficiency of factor IX (hemophilia B, also called Christmas disease) results in impaired thrombin generation and a bleeding diathesis of variable severity depending on residual factor IX activity levels.

Question 6

What is the pharmacokinetic profile of dalcinonacog alfa?

Accepted Answer

Dalcinonacog alfa exhibits dose-proportional pharmacokinetics when administered intravenously. Following a single 75 IU/kg dose, the mean incremental recovery is approximately 0.98 IU/dL per IU/kg. The mean terminal half-life is 22–25 hours, which is consistent with other recombinant and plasma-derived factor IX products. The volume of distribution at steady state is approximately 150–200 mL/kg, reflecting distribution primarily within the intravascular space with some extravascular distribution. Clearance averages approximately 5–7 mL/hr/kg. These pharmacokinetic parameters support twice-weekly dosing for prophylactic regimens, though individual dose adjustments based on achieved factor IX trough levels and bleeding phenotype are recommended.

Question 7

What is the risk of inhibitor development with dalcinonacog alfa?

Accepted Answer

Inhibitor development — the formation of neutralizing IgG antibodies against factor IX — is the most serious complication of factor IX replacement therapy. In previously treated patients (PTPs), the incidence of inhibitor development is generally low (1–5%), and no cases of inhibitor formation were reported in the clinical development program for dalcinonacog alfa. Risk is substantially higher in previously untreated patients (PUPs), particularly those with severe gene deletions or nonsense mutations. Inhibitors can render factor IX replacement therapy ineffective and may be associated with severe allergic or anaphylactic reactions upon re-exposure. Patients receiving dalcinonacog alfa should be monitored for signs of inhibitor development, especially during the first 20 exposure days.

Question 8

How does dalcinonacog alfa compare to extended half-life factor IX products?

Accepted Answer

Dalcinonacog alfa has a standard half-life of approximately 22–25 hours, while newer extended half-life (EHL) factor IX products — such as eftrenonacog alfa (Alprolix, Fc-fusion) and nonacog beta pegol (Rebinyn, PEGylated) — achieve half-lives of 82–104 hours and 93–115 hours, respectively. EHL products allow less frequent dosing (weekly or every 10–14 days vs. twice weekly), potentially improving adherence and quality of life. However, dalcinonacog alfa remains a well-established option with extensive real-world clinical experience, and some patients and clinicians prefer standard half-life products for their predictable pharmacokinetics and shorter duration of effect, which may be advantageous in certain surgical or acute bleeding contexts.

Question 9

Is dalcinonacog alfa safe during pregnancy?

Accepted Answer

There are limited clinical data on the use of dalcinonacog alfa during pregnancy. Hemophilia B is an X-linked recessive disorder that predominantly affects males, but female carriers may have reduced factor IX levels and experience bleeding complications, particularly during delivery. Animal reproduction studies have not been conducted with dalcinonacog alfa. The decision to use factor IX replacement during pregnancy or delivery should be made on a case-by-case basis, weighing the potential benefit against any unknown risks. Factor IX levels should be monitored closely, and management should be coordinated between hematology and obstetrics teams.

Question 10

What monitoring is required during treatment with dalcinonacog alfa?

Accepted Answer

Patients receiving dalcinonacog alfa require regular monitoring of factor IX activity levels, particularly when initiating therapy, adjusting doses, or managing acute bleeds or surgical procedures. One-stage clotting assays (aPTT-based) are the standard method for measuring factor IX activity. Additionally, patients should be monitored for the development of inhibitors using Bethesda assays, especially during the initial exposure days. Complete blood counts, signs of thromboembolic events, and assessment for hypersensitivity reactions should also be part of routine monitoring. For prophylactic regimens, trough factor IX levels are measured to ensure adequate protection against spontaneous bleeds, with target troughs typically above 1–5% depending on clinical goals.

Origin / Manufacturer	Recombinant (CHO cell-derived)
Regulatory Status	FDA-Approved (2015)cGMP Manufactured
Active Components	Dalcinonacog alfa (recombinant factor IX)SucroseL-histidinePolysorbate 80
Storage	Store at 2–8°C (36–46°F). Do not freeze. Reconstituted solution should be used within 3 hours.
Shelf Life	24 months when stored at recommended conditions
Form Factor	Lyophilized powder for intravenous injection (250, 500, 1000, 1500 IU vials)

Dalcinonacog Alfa

Specifications

Frequently Asked Questions

Related Peptides

BPC-157

Follistatin-344

IGF-1 LR3

Thymosin Beta-4